Medtronic Continues To Deal In Diabetes
This article was originally published in Start Up
DreaMed, the Israel-based developer of the GlucoSitter glucose control system announced an exclusive worldwide development and license agreement with Medtronic for the development and marketing of the MD-Logical Artificial Pancreas algorithm in Medtronic’s insulin pumps. This is the third Medtronic investment in a diabetes firm made public in the past month.
You may also be interested in...
The quest to bring an artificial pancreas to market has taken some giant steps forward recently, as major players continue to produce impressive data from clinical studies that measure the use of various insulin pumps, continuous glucose monitors (CGMs), and algorithms. Improvements in CGM sensor technology have helped move AP research, and competition is proving to be a driving force on the road to producing a commercial product that could be within two or three years from reaching the market.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.